Jared A. Silverman

Jared A. Silverman


Head of Translational Discovery

As head of translational discovery at the Bill & Melinda Gates Medical Research Institute, Jared A. Silverman, Ph.D., drives products from idea to commercialization in disease areas that disproportionately impact vulnerable populations worldwide.

Jared has more than 20 years of experience in drug discovery spanning multiple therapeutic areas, with a primary focus on antibiotics for the treatment of serious hospital infections. Prior to joining Gates MRI, Jared was senior vice president of research at Kaleido Biosciences, where he was responsible for building a drug discovery platform to identify novel modulators of the microbiome for the prevention and treatment of disease. From 1997 to 2015, he was a member of the research team at Cubist Pharmaceuticals (including five years as vice president of biology) where he contributed to the discovery of three novel antibiotics that entered clinical development.

Jared has served on the Board of Directors of Auspherix and Procarta Biosciences, and is an editor for Antimicrobial Agents and Chemotherapy. He earned his Ph.D. in Microbiology and Molecular Genetics from Harvard University.